John Henderson, DO
Family Medicine · Columbus, GANPI 1477597979
Payments from drug & device makers
Across 445 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Bayer$947
- Lilly USA, LLC$670
- Boehringer Ingelheim$484
- Astellas Pharma US Inc$422
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,330100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 97 | $1,425 |
| AstraZeneca | 65 | $1,094 |
| Bayer | 45 | $947 |
| Lilly USA, LLC | 44 | $670 |
| Boehringer Ingelheim | 29 | $484 |
| Astellas Pharma US Inc | 22 | $422 |
| Pfizer | 26 | $380 |
| Johnson & Johnson | 21 | $338 |
| Novartis | 16 | $264 |
| Sanofi-aventis U.S. LLC | 13 | $210 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $173 |
| Sumitomo Pharma America, Inc. | 8 | $158 |
| Eisai Inc. | 7 | $115 |
| Merck | 9 | $114 |
| AbbVie(2 entities) | 6 | $107 |
| Catalyst Pharmaceuticals, Inc. | 3 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Aytu Biopharma, Inc. | 3 | $48 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Exact Sciences | 2 | $41 |
| Abbott | 2 | $40 |
| Amgen | 2 | $29 |
| Ossur Americas, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| GSK | 1 | $13 |
How this compares
$7,341 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 366 | $154,290 |
| XtandiEnzalutamide | 13 | $92,428 |
| JardianceEmpagliflozin | 103 | $83,088 |
| FarxigaDapagliflozin Propanediol | 104 | $64,848 |
| RybelsusSemaglutide | 34 | $62,667 |
| XareltoRivaroxaban | 92 | $39,071 |
| MounjaroTirzepatide | 19 | $35,311 |
| JanuviaSitagliptin Phosphate | 46 | $34,794 |
| KerendiaFinerenone | 21 | $31,263 |
| TrulicityDulaglutide | 32 | $28,866 |
| JanumetSitagliptin Phos/Metformin Hcl | 34 | $25,847 |
| OzempicSemaglutide | 22 | $25,243 |
| EntrestoSacubitril/Valsartan | 28 | $14,864 |
| Potassium Chloride | 284 | $13,739 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $12,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $380 | $154,290366 claims |
| Astellas Pharma US IncXtandi | $422 | $92,42813 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $484 | $90,693119 claims |
| Novo NordiskRybelsus, Ozempic | $1,425 | $87,91056 claims |
| AstraZenecaFarxiga | $1,094 | $64,848104 claims |
| Lilly USA, LLCMounjaro, Trulicity | $670 | $64,17751 claims |
| MerckJanuvia, Janumet | $114 | $60,64180 claims |
| Johnson & JohnsonXarelto | $338 | $39,07192 claims |
| BayerKerendia | $947 | $31,26321 claims |
| NovartisEntresto | $264 | $14,86428 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $158 | $6,20426 claims |
| GSKIncruse Ellipta | $13 | $4,52613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Columbus
- Joseph SurberColumbus$16.6M
- Jeffrey KingsleyColumbus$8.1M
- Bantwal BaligaColumbus$117K
- Megbewe OkorobaColumbus$61K
- Kimberly Brown-GullattColumbus$35K
- Angela RitterGainesville$15.8M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.